Frederic Chereau, LogicBio Therapeutics CEO
Months later, LogicBio exits FDA clinical hold for gene editing drug but won't restart trial until next quarter
LogicBio Therapeutics has received some good news this morning as the FDA has lifted a three-month clinical hold on one of the company’s primary trials for a potential gene editing drug, but the trial isn’t expected to resume until next quarter.
Enrollment in the Phase I/II trial, dubbed SUNRISE, for LogicBio’s gene editing therapy LB-001 will be allowed to resume. The trial is focused on pediatric patients with methylmalonic acidemia, or MMA, an inherited disorder in which the body is unable to process certain proteins and lipids properly.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters